Compare SATS & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SATS | ILMN |
|---|---|---|
| Founded | 2007 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.8B | 20.6B |
| IPO Year | 2007 | 2000 |
| Metric | SATS | ILMN |
|---|---|---|
| Price | $108.47 | $134.44 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 5 | 16 |
| Target Price | $108.80 | ★ $117.31 |
| AVG Volume (30 Days) | ★ 6.3M | 1.6M |
| Earning Date | 11-06-2025 | 02-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 4.46 |
| Revenue | ★ $15,175,913,000.00 | $4,288,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.24 |
| P/E Ratio | ★ N/A | $30.15 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.90 | $68.70 |
| 52 Week High | $111.39 | $153.06 |
| Indicator | SATS | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 73.62 | 60.74 |
| Support Level | $99.90 | $132.93 |
| Resistance Level | $109.26 | $138.80 |
| Average True Range (ATR) | 5.73 | 3.96 |
| MACD | 0.29 | -0.50 |
| Stochastic Oscillator | 88.15 | 66.50 |
Satellite television provides the bulk of EchoStar's revenue. The firm serves about 5 million US satellite customers, about 10% of the traditional television market. It also serves 2 million customers under the Sling brand. EchoStar has also amassed an extensive portfolio of spectrum licenses and is building a nationwide wireless network. It acquired Sprint's prepaid business, serving approximately 7 million customers, primarily under the Boost brand. The firm has agreed to sell a portion of its wireless licenses to AT&T and will rely heavily on the AT&T network to serve customers. EchoStar's legacy businesses provide satellite telecom services and equipment to businesses and consumers, including about 800,000 internet customers.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.